Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Camcevi

(kam-SEE-vee)
A drug used to treat adults with advanced prostate cancer. Camcevi initially causes the pituitary gland to make more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), temporarily increasing testosterone levels in men. With continued use, Camcevi lowers the amount of LH and FSH the pituitary gland releases, leading to a drop in testosterone levels. Camcevi may stop the growth of cancer cells that need testosterone to grow. It is a type of hormone therapy called a luteinizing hormone-releasing hormone (LHRH) agonist. Also called leuprolide mesylate.
Search NCI's Dictionary of Cancer Terms